The efficacy of PD-1 and PD-L1 blocking antibodies to relieve this suppression and reinvigorate anti-tumor immune responses in PCa remains unclear, although one recent clinical trial suggests it may be beneficial for a subset of patients [89]. Here, CD274 is linked to neoplasm.